Based on 301 events , median progression-free survival was 110 months ( 95 % CI 80-139 ) in the dabrafenib and trametinib group and 88 months ( 59-93 ) in the dabrafenib only group ( HR 067 , 95 % CI 053-084 ; p = 00004 ; unadjusted for multiple testing ) .